LONDON, 29 January 2019
Arix Bioscience plc (LSE:ARIX) (“Arix”), a global healthcare and life science company supporting medical innovation, today notes that Harpoon Therapeutics Inc. (“Harpoon”) has filed an amended registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the “SEC”) relating to a proposed underwritten initial public offering in the United States of shares of Harpoon’s common stock.
The registration statement discloses an expected pricing range for the proposed offering of U.S.$13.00- U.S.$15.00 per share of common stock. This would represent an increase in value of Arix’s current shareholding in Harpoon (compared to the £20.2 million sterling holding value) of £4.2 million – £7.9 million. The proposed maximum aggregate offering amount specified in the filing is U.S.$93.15 million, which assumes that the public offering price is at the top of the expected pricing range and includes the option that is proposed to be granted to the underwriters to purchase additional shares of common stock.